Fulcrum Therapeutics to evaluate losmapimod in Phase III trial as a potential treatment for COVID-19.
Fulcrum Therapeutics, Inc. announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19 . Fulcrum has submitted an investigational new drug (IND) application to support… read more.